EFFICACY OF PROGESTERONE VAGINAL SUPPOSITORIES IN ALLEVIATION OF NERVOUS SYMPTOMS IN PATIENTS WITH PREMENSTRUAL-SYNDROME

被引:38
作者
BAKER, ER
BEST, RG
MANFREDI, RL
DEMERS, LM
WOLF, GC
机构
[1] Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, 29203, South Carolina
[2] Department of Psychiatry, The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania
关键词
PROGESTERONE; PREMENSTRUAL SYNDROME; DEPRESSION; ANXIETY; BETA ENDORPHIN;
D O I
10.1007/BF02211800
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: To fur ther investigate the efficacy of progesterone in the treatment of the symptoms of premenstrual syndrome (PMS). Materials and Methods: From an initial cohort of 25 subjects diagnosed with moderate to severe PMS, 17 reproductive age females completed the 7-month, double-blind, placebo controlled trial rising 200-mg vaginal progestone suppositories. Multiple modalities for evaluating symptoms were employed, including the Spielberger self-evaluation rating, the Beck depression inventory, and the Hamilton anxiety scale. In addition, each subject was interviewed by a psychiatrist on a monthly basis; ovulation was determined monthly using a basal body temperature chart; serum hormonal assays included beta endorphin, progester one, follicle stimulating hormone, luteinizing hormone, estradiol, and prolactin. Results: Hormonal assays confirmed no differences between treatment and control groups. Overall scores on all test vehicles were likewise not significantly different between the two groups; however, in the subcategory of nervous symptoms, a significant improvement was found in symptoms relating to tension, mood swings, irritability, anxiety and lack of control. Conclusions: Metabolites of progesterone (pregnanolone and allopregnanolone) may play a physiologic role as anxiolytic agents, perhaps modifying mood and anxiety; the current study confirms the utility of twice daily, 200-mg progester one vaginal suppositories, in the alleviation of some PMS symptoms relating to anxiety and irritability. Further evaluation may be warranted to ascertain which patients in the known heterogeneous PMS population may be most likely to benefit from such treatment.
引用
收藏
页码:205 / 209
页数:5
相关论文
共 15 条
[1]  
Frank R.T., The hormonal basis of premenstrual tension, Archives of Neurology And Psychiatry, 26, pp. 1053-1057, (1931)
[2]  
Horney K., Premenstrual tension, Reminine Psychology, pp. 99-106, (1931)
[3]  
Reid R.L., Premenstrual syndrome, Curr Probl Obstet Gynecol Fertil, 8, (1985)
[4]  
Rubinow D.R., Hoban M.C., Grover G.N., Galloway, Roy-Byrne P., Anderson R., Merriman G.R., Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects, Am J Obstet Gynecol, 158, pp. 5-11, (1988)
[5]  
Dalton K., The Premenstrual Syndrome and Progesterone Therapy, (1984)
[6]  
Mortola J.F., Girton L., Fischer U., Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin, J Clin Endocrinol Metab, 71, (1991)
[7]  
Freeman E., Rickels K., Sondheimer S.J., Polansky M., Ineffectiveness of progesterone suppository treatment for premenstrual syndromes, J Am Med Assoc, 264, pp. 349-353, (1990)
[8]  
Dennerstein L., Spencer-Gardner C., Gotts G., Brown J.B., Smith M.A., Burrows G.D., Progesterone and the premenstrual syndrome: a double-blind crossover trial, Br Med J, 290, pp. 1617-1621, (1985)
[9]  
Freeman W.E., Purdy R.H., Coutifaris C., Rickels K., Paul S.M., Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers, Neuroendocrinology, 58, pp. 478-484, (1993)
[10]  
Freeman E.W., Weinstock L., Rickels K., Sondheimer S.J., Coutifaris C., A placebo-controlled study of effects of oral progesterone on performance and mood, Br J Clin Pharmacol, 33, pp. 293-298, (1992)